C4 Therapeutics shareholders approve doubling authorized common shares to 300M at annual meeting

C4 Therapeutics, Inc.

Shareholders elected Ronald Cooper, Donna Grogan, and Steven Hoerter as Class II directors for terms expiring 2028.
Non-binding advisory vote on executive compensation passed with 48.85M for vs 0.89M against.
Ratification of KPMG as auditor for FY2025 approved with 60.18M for, 0.08M against.
Amendment to increase authorized common shares from 150M to 300M approved with 39.55M for, 20.66M against.
Certificate of Amendment filed and effective June 18, 2025.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.95

C4 Therapeutics, Inc.: Stockholders approved an amendment to the Fifth Amended and Restated Certificate of Incorporation to increase authorized common shares from 150,000,000 to 300,000,000, which was filed and became effective on June 18, 2025 (effective 2025-06-18).

Change: charter amendment
Effective: 2025-06-18

Exact text from the filing

On June 18, 2025 , the Company filed a Certificate of Amendment to the Company’s Fifth Amended and Restated Certificate of Incorporation (the “ Certificate of Amendment ”) with the Secretary of State of the State of Delaware and the Certificate of Amendment became effective on filing.

View on SEC.gov

Browse all governance changes →

C4 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-25-032155

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.